drugset / Trial / NCT00700310

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00700310

Phase 3 Completed 712 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.

Timeline

Start
2008-08
Primary completion
2009-08
Completion
2010-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Perampanel Small molecule 2 mg
Comparator Perampanel Small molecule 4 mg
Comparator Perampanel Small molecule 8 mg

Indications